Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG known ✓ | Q16739 | 3/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 18/20 | 1.00 |
| ▸ | GBA1 | P04062 | 7/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | MGAM | O43451 | 2/20 | 1.00 |
| ▸ | SI | P14410 | 2/20 | 1.00 |
| ▸ | AGL | P35573 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miglustat SCHEMBL19627562 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL7911410 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL11921340 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL13175027 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL246893 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL23503067 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20577242 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20576705 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20769803 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL19627563 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270826-A1 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | DELTA 4 GMBH (AT) | 2023-08-31 | — | — | US | disclosed |
| EP-3957320-B1 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | AMICUS THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230220320-A1 | Method For Capturing And Purification Of Biologics | AMICUS THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| EP-3957320-A1 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | Amicus Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022023533-A2 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | DELTA 4 GMBH (AT) | 2022-02-03 | — | — | WO | disclosed |
| EP-3397273-B1 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | AMICUS THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10857212-B2 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | AMICUS THERAPEUTICS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10227577-B2 | Method for selection of high M6P recombinant proteins | AMICUS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170335301-A1 | Method for Selection of High M6P Recombinant Proteins | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-11-23 | — | — | US | disclosed |
| WO-2017173059-A1 | METHOD FOR SELECTION OF HIGH M6P RECOMBINANT PROTEINS | AMICUS THERAPEUTICS, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017117407-A1 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170189497-A1 | Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-07-06 | — | — | US | disclosed |
| EP-0624652-B1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO CO (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1132370-A2 | Process for producing n-substituted polyhydroxy nitrogen-containing heterocyles | MONSANTO COMPANY (US) | 2001-09-12 | — | — | EP | disclosed |
| US-5401645-A | Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium | MONSANTO COMPANY (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0624652-A1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO COMPANY (US) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189497-A1 | Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease | GAA, MAN2B1, MANBA | UGCG 40/4885GBA2 19/4885GBA1 9/4885 |
| US-10227577-B2 | Method for selection of high M6P recombinant proteins | M6PR, MAN2B1, MTAP | UGCG 393/4885GBA2 80/4885GBA1 29/4885 |
| US-20170335301-A1 | Method for Selection of High M6P Recombinant Proteins | M6PR, MAN2B1, MTAP | UGCG 393/4885GBA2 80/4885GBA1 29/4885 |
| US-20230270826-A1 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | GLP1R, SLC5A1, DPP4 | UGCG 2269/4885GBA2 3435/4885GBA1 1375/4885 |
| US-10857212-B2 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | GAA, MAN2B1, MANBA | UGCG 40/4885GBA2 19/4885GBA1 9/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | UGCG 14/4885GBA2 3/4885GBA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.